Skip to main navigation Skip to search Skip to main content

The Potential Clinical and Economic Value of a Human Papillomavirus Primary Screening Test That Additionally Identifies Genotypes 31, 45, 51, and 52 Individually

  • Lindsey Asti
  • , Colin Hopley
  • , Cameron Avelis
  • , Sarah M. Bartsch
  • , Leslie E. Mueller
  • , Molly Domino
  • , Sarah N. Cox
  • , Jeffrey C. Andrews
  • , Samuel L. Randall
  • , Owen J. Stokes-Cawley
  • , Caitlin Asjes
  • , Bruce Y. Lee
  • City University of New York
  • Becton, Dickinson and Company
  • BD Diagnostics

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Background Although current human papillomavirus (HPV) genotype screening tests identify genotypes 16 and 18 and do not specifically identify other high-risk types, a new extended genotyping test identifies additional individual (31, 45, 51, and 52) and groups (33/58, 35/39/68, and 56/59/66) of high-risk genotypes. Methods We developed a Markov model of the HPV disease course and evaluated the clinical and economic value of HPV primary screening with Onclarity (BD Diagnostics, Franklin Lakes, NJ) capable of extended genotyping in a cohort of women 30 years or older. Women with certain genotypes were later rescreened instead of undergoing immediate colposcopy and varied which genotypes were rescreened, disease progression rate, and test cost. Results Assuming 100% compliance with screening, HPV primary screening using current tests resulted in 25,194 invasive procedures and 48 invasive cervical cancer (ICC) cases per 100,000 women. Screening with extended genotyping (100% compliance) and later rescreening women with certain genotypes averted 903 to 3163 invasive procedures and resulted in 0 to 3 more ICC cases compared with current HPV primary screening tests. Extended genotyping was cost-effective ($2298-$7236/quality-adjusted life year) when costing $75 and cost saving (median, $0.3-$1.0 million) when costing $43. When the probabilities of disease progression increased (2-4 times), extended genotyping was not cost-effective because it resulted in more ICC cases and accrued fewer quality-adjusted life years. Conclusions Our study identified the conditions under which extended genotyping was cost-effective and even cost saving compared with current tests. A key driver of cost-effectiveness is the risk of disease progression, which emphasizes the need to better understand such risks in different populations.

Original languageEnglish
Pages (from-to)370-380
Number of pages11
JournalSexually Transmitted Diseases
Volume48
Issue number5
DOIs
StatePublished - 1 May 2021
Externally publishedYes

Fingerprint

Dive into the research topics of 'The Potential Clinical and Economic Value of a Human Papillomavirus Primary Screening Test That Additionally Identifies Genotypes 31, 45, 51, and 52 Individually'. Together they form a unique fingerprint.

Cite this